Non-immune Hydrops Fetalis - Experience of a level III Neonatal Intensive Care Unit by Filipa Batschelet Barros
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2016/2017 
 
 
 
 
 
 
Filipa Batschelet Barros 
Non-immune Hydrops Fetalis - Experience of  
a level III Neonatal Intensive Care Unit 
 
Hidrópsia Fetal Não Imune – Experiência de uma 
Unidade de Cuidados Intensivos Neonatal terciária 
 
 
 
 
 
 
 
 
 
 
 
 
 
Março, 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Filipa Batschelet Barros 
Non-immune Hydrops Fetalis - Experience of  
a level III Neonatal Intensive Care Unit 
 
Hidrópsia Fetal Não Imune – Experiência de uma 
Unidade de Cuidados Intensivos Neonatal terciária 
 
 
Mestrado Integrado em Medicina 
 
 
Área: Pediatria 
Tipologia: Dissertação 
 
Trabalho efectuado sob a Orientação de:  
Doutora Hercília Guimarães 
 
Trabalho organizado de acordo com as normas da revista: 
Minerva Pediatrica 
 
 
 
 
Março, 2017
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Aos meus pais, irmãos e Ricardo
Non-immune Hydrops Fetalis – Experience of a level III 
Neonatal Intensive Care Unit 
 
Filipa Barros1, Gustavo Rocha1,2, Filipa Flor-de-Lima1,2, 
Henrique Soares1,2, Hercília Guimarães1,2 
 
1Faculty of Medicine, Porto University, Porto, Portugal 
2 Neonatal Intensive Care Unit, Centro Hospitalar de São João, Porto, Portugal 
 
Abstract  
BACKGROUND: The aim of this study was to evaluate the experience of our level III 
Neonatal Intensive Care Unit (NICU) with Non-Immune Hydrops Fetalis (NIHF), and 
thus contribute to the improvement of our practice in prenatal diagnosis and postnatal 
clinical management of neonates. 
METHODS: We analysed the clinical records of neonates admitted to NICU of Centro 
Hospitalar de São João do Porto between 1 January 1997 and 31 December 2016, 
with diagnosis of NIHF. Demographic data and information regarding gestation, 
delivery and neonatal period were examined.  
RESULTS: We found 23 patients with NIHF, out of which 12 (52.2 %) died and 11 
(47.8 %) survived. The mean gestational age at birth was significantly lower among the 
deceased patients (30.6 ± 2.2 weeks). Concerning the morbidity, all the disorders 
evaluated were more frequently found in the deceased group, except for necrotizing 
enterocolitis; however, the only statistically significant difference was the frequency of 
anemia, which was higher in the deceased group. The commonest etiology of NIHF 
was congenital heart disease (52.2%), which was significantly more frequent among 
the survivors. Specific treatment and antiarrhytmics were administered significantly 
more frequently among the survivors. Amines, thoracocentesis, paracentesis were 
significantly more used in the deceased. 
CONCLUSIONS: Despite improvements in healthcare, mortality rates of NIHF are high. 
Some causes of NIHF are responsive to therapy, such as cardiac diseases, which 
confers a lower mortality. The cornerstone of management of NIHF is based on the 
underlying etiology, which determines prognosis, appropriate treatment and recurrence 
risk of future pregnancies.  
 
Introduction 
Hydrops fetalis is characterized by pathological fluid accumulation in fetal soft 
tissues and serous cavities. The features are usually detected by ultrasound, and are 
defined as the presence of two or more abnormal fluid collections, such as ascites, 
pleural effusions, pericardial effusion, and generalized skin edema (skin thickness >5 
mm). [1] Although polyhydramnios and placental thickening are frequently associated 
with hydrops fetalis [2], they are not used as diagnostic criteria. 
This disease is classified in immune or non-immune hydrops. Non-immune 
hydrops fetalis (NIHF) refers specifically to cases not caused by red cell 
alloimmunization. With advances in prenatal diagnosis and routine use of Rh(D) 
immune globulin in rhesus-negative mothers, alloimmunization and associated immune 
hydrops has dramatically decreased. [1, 3] Therefore, actually most cases (90%) have 
a non-immune etiology, with prevalence in studies reported as 1:1700-3000 
pregnancies.[1, 3, 4] 
 The differential diagnosis is extensive, as it can result from a large number of 
underlying pathologies, including those affecting lymphatic, cardiovascular, pulmonary, 
renal, hematologic or gastrointestinal systems, and also chromosomal abnormalities, 
infections and metabolic diseases.[5-7] Overall, chromosomal abnormalities, 
cardiovascular and hematologic diseases are the most common causes of NIHF.[1, 6] 
Despite  exhaustive  investigations,  the  etiology  may  remain  idiopathic in  15%  to  
25%  of  patients.[2]  
 The prognosis of NIHF differs markedly between different etiological groups, but 
overall mortality rates are high. [5, 6, 8] More recently, earlier and advanced pre natal 
diagnosis and interventions, and developed post-natal management had shown to 
improve survival in selected cases. However, this disease still represents a challenge 
for physicians all over the world, so all the studies and information are valuable and 
useful to understand the best way to deal with it.  
 The aim of this study was to evaluate the experience of our level III Neonatal 
Intensive Care Unit (NICU) with NIHF, and thus contribute to the improvement of our 
practice in prenatal diagnosis and postnatal clinical management of these neonates; 
and to add some useful information to the current literature. 
 
Material and methods 
We conducted an observational retrospective study. The study population 
included all neonates admitted to the level III NICU of Centro Hospitalar São João do 
Porto (Portugal) between 1 January 1997 and 31 December 2016, with a diagnosis of 
NIHF. Cases diagnosed with immune hydrops fetalis were excluded from the study. 
Demographic data and information regarding gestation, delivery and neonatal period 
were extracted from the medical records (appendix 1). Autopsy study was assessed in 
10 of the 12 deceased children (one was not available and the other was refused by 
the parents). 
NIHF was defined as an abnormal fluid collection in two or more areas of the 
fetal body (ascites, pleural effusion, pericardial effusion, or skin edema), not caused by 
red cell alloimmunization.  
Anemia was defined by a concentration of hemoglobin or a hematocrit less than 
two standard deviation than the mean of a normal population with the same age and 
sex. [9] Intraventricular haemorrhage (IVH) was classiﬁed according to Papile et al – in 
our study we just considered grade 3 (transfontanellar ultrasound demonstrating 
intraventricular bleeding with ventricular dilation) and grade 4 (transfontanellar 
ultrasound demonstrating intraventricular bleeding with parenchymal involvement.[10] 
The diagnosis of bronchopulmonary dysplasia (BPD) was based on the National 
Institute of Child Health and Human.[11] Hyaline membrane disease (HMD) was 
defined based on the european guidelines.[12] Diagnosis of hemodynamically 
signiﬁcant patent ductus arteriosus (PDA) was based on bidimensional heart 
ultrasound, using Doppler to analyze the blood flow and show the presence of 
shunt.[13, 14] Proven neonatal sepsis was deﬁned as any systemic bacterial or fungal 
infection documented by a positive blood culture. Diagnosis of necrotizing enterocolitis 
(NEC) was established by the criteria of Bell.[15] Congenital anomalies, also known as 
birth defects, congenital disorders or congenital malformations, were defined as 
structural or functional anomalies that occur during intrauterine life and can be 
identified prenatally, at birth, or sometimes may only be detected later in infancy.[16] 
We classified the NIHF into 8 categories: congenital heart disease, 
chromosomal abnormality, congenital infection, urinary tract abnormality, lymphatic 
dysplasia, fetal tumors, inborn errors of metabolism and idiopathic. Congenital heart 
disease includes arrhythmias and structural defects. 
Prenatal invasive diagnostic testing was considered if amniocentesis or 
cordocentesis was realized during the pregnancy. Fetal intervention was performed in 
selected patients, either by pharmacological agents or thoracentesis. Specific 
treatment was defined as any treatment (pharmacological or not) directed to the 
underlying etiology of NIHF.  
 The statistical analysis was performed using SPSS® for Windows®, version 20. 
Continuous variables with symmetric distribution were characterized by mean (± 
standard deviation), whereas continuous variables with asymmetric distribution were 
described by median (medium-maximum). Categorical variables were characterized by 
absolute and relative frequencies. Parametric testes (independent t test) or non-
parametric tests (Mann-Whitney U test) were used to compare symmetric or 
asymmetric continuous variables, respectively. To compare categorical variables, Chi-
Squared or Fisher’s exact test were used, the latter for expected values less than 5. A 
multivariate analysis by logistic regression was performed to evaluate predictive factors 
for death. A p-value less than 0.05 was considered statistically significant.  
The study was approved by the Ethics Committee of the Centro Hospitalar de 
São João/ Faculdade de Medicina da Universidade do Porto.  
 
Results 
There were 57,773 births registered at the hospital, during the period of the 
study and a total of 23 (0.04%) newborns diagnosed with NIHF were admitted to the 
NICU during the same period, out of which 12 (52.2 %) died and 11 (47.8 %) survived.  
Maternal and perinatal data of all cases of NIHF are shown in table 1 and in 
table 2 we can observe maternal, perinatal and neonatal morbidity of NIHF patients, 
comparing deceased and survivors.  
The most common cause of NIHF was congenital heart disease (52.2%), which 
was significantly more frequent among the survivors (p=0.001). The second most 
common etiologies were congenital TORCH infections (8.7%) and lymphatic dysplasia 
(8.7%), followed by chromosomal abnormalities (4.3%), congenital nephrotic syndrome 
(4.3%), cardiac rhabdomyoma (4.3%) and inborn errors of metabolism (4.3%). With 
respect to congenital heart diseases, three different arrhythmias (supraventricular 
tachycardia, Wolff-Parkinson-White syndrome (WPW), Atrial Flutter) and two types of 
structural defects (Atrial Septal Defect and Right-ventricle Hypoplasia) were diagnosed. 
Tetrasomy 9p was the only chromosomal abnormality detected (Tables 3 and 4). 
 A total of 11 (47.8%) neonates received specific treatment, and the frequency 
was significantly greater among the survivors (72.7% survivors, 25.0% deceased; 
p=0.039). Antiarrhythmics were also administered significantly more frequently among 
the survivors (p=0.001). Amines and thoracocentesis or paracentesis were significantly 
more used in the deceased patients (p<0.001 and p=0.012, respectively). Other 
treatments carried out included diuretics (43.5%), antibiotics (69.5%), surfactant 
(52.2%), blood transfusions (65.2%), mechanical ventilation (78.3%) and oxygen 
therapy (73.9%), without significant differences between the two groups (Tables 3 and 
5).  
A low gestational age at birth and the need to perform thoracocentesis or 
paracentesis were identified as the predictive factors of mortality in the multivariate 
analysis (Table 6). 
 
Discussion 
In our study, we reviewed the clinical characteristics, the treatment performed 
and the outcome (death/survived) of newborns with non-immune hydrops fetalis in a 
tertiary-referral center, during a 20 year period. 
Our data shows that the prevalence of NIHF at our centre is approximately 1: 
2500, which is in agreement with other studies.[1, 4, 17] 
We notice that the mean birth weight and the mean gestational age at birth 
were lower in the fetal death than the live birth cases; and the reverse happened with 
maternal age, which was higher in the deceased patients. These three factors are 
generally associated with higher risk pregnancies, so it’s easy to understand that 
neonates with these characteristics tend to die more. Just like our study, lower 
gestational age at birth has been identified as a risk factor for mortality in NIHF in 
several other recent studies [8, 18, 19] and association between prematurity and poor 
outcome has been shown undoubtedly.[19, 20] We interpret this as a result of the 
additional morbidity conferred by the prematurity and by its complications. Besides, the 
need to perform a preterm delivery may reflect a greater severity of NIHF.[19]  
Prenatal fetal intervention, namely pharmacological therapy and 
thoracocentesis, was more frequently observed in the survivors, although without 
statistically significant difference. This is consistent with other studies [1, 6, 7, 17], and 
highlights the importance of the selection of the patients in which fetal therapy is 
effective. This usually requires evaluation at a specialized center, in which a careful 
consideration of risks and benefits is carried out.  
A prenatal NIHF diagnosis was made in 82.6%, a satisfactory number of 
patients. However, the main difficulty is not to identify the presence of a hydropic fetus 
on the ultrasound, but to recognize the underlying etiology. It has been reported that 
the cause of hydrops can be determined in about 60-85% of cases.[1, 21] The 
identification of the cause of hydrops is essential. First, because the prognosis of the 
neonate is directly dependent on the underlying condition.[17, 20] Second, it enables 
the institution of management strategies and the treatment of potentially treatable 
conditions, such as arrhythmias. Finally, it allows to rule out genetic and inherited 
metabolic disorders that have a greater risk of recurrence in future pregnancies.[1] In 
our study, one-quarter of all cases had no identified etiology (idiopathic cause), which 
is consistent with the literature.[2, 17, 22, 23] 
The etiology of NIHF varies widely among different places and populations.[24] 
In most series, congenital heart diseases are the most common cause of NIHF, 
accounting for about 20% of cases.[1, 2, 7, 21, 25] These results are similar to the 
results in our study, in which the cardiac etiologies, especially arrhythmias, assumed 
the majority of the cases. However, in our study, they were responsible for a higher 
amount of cases, namely 52.2% (versus 20% reported in literature). When we analyzed 
this finding, we discovered that 75% of these NIHF caused by congenital heart disease 
occurred after 2007, the year when the pregnancy interruption law was approved in our 
country. Therefore, this may due to a better selection of neonates more able to survive, 
i.e. since the overall prognosis of cardiac NIHF is better than non-cardiac NIHF, 
pregnancy termination was more frequent among the latter, leading to the higher 
prevalence of congenital heart disease in our study. Also, our hospital is the only 
referral center for congenital cardiac diseases in the north of the country. The most 
commonly found arrhythmias were supraventricular tachycardia and atrial flutter, which 
is in agreement with other series.[1, 26] Notably, one of the most important findings of 
our study was the significantly higher frequency of congenital heart diseases among 
the survivors. This is probably due to two reasons: first, the prenatal fetal therapy with 
transplacentary antiarrhythmics is very effective for these tachycardias [1, 20, 26, 27]; 
second, they have been shown to be the most treatable of the cardiac causes of NIHF 
[2, 6, 7], a consequence of the excellent response to postnatal antiarrhythmics and 
cardioversion. This finding is supported by other studies that showed a lower mortality 
rate when the cause of NIHF was supraventricular tachycardia that responded to 
maternal treatment.[25, 27, 28] Apart from cardiac disorders, chromosomal 
abnormalities and hematologic diseases are reported as part of the most frequent 
etiologies, with frequencies between 7-16% and 4-12%, respectively.[1, 6, 19, 29] 
However, in our study, these conditions were not very often diagnosed. Concerning 
chromosomal abnormalities (4.3%), it was most likely due to a high rate of pregnancy 
termination of chromosomally abnormal pregnancies. With respect to hematologic 
diseases (0%), this may be related to the very low prevalence of thalassaemia in our 
local population. This disease is very common in Southeast Asian populations, 
accounting for 55% of NIHF in Southern China [1, 2, 30], but not in Western Europe. 
Other frequently reported etiologies include infections and lymphatic dysplasia, which 
were the second most common etiologies in our study. Infections were present in 8.7% 
patients, consistent with other series, in which such infections account for 5-10% of 
NIHF.[1, 2, 6, 31, 32] Lymphatic dysplasia was also responsible for 8.7% of NIHF, 
similar to other reports.[1] Finally, the remaining etiologies were congenital nephrotic 
syndrome, cardiac rhabdomyoma and inborn errors of metabolism, each accounting for 
4.3% of the cases, which is in agreement with other series.[1, 6, 7, 25, 33] In the last 
few years, inborn errors of metabolism have been drawing the attention of physicians. 
Although they are an uncommon cause of NIHF, they entail a high risk of recurrence. 
Consequently, the identification of such disorder should prompt specific screening in 
future pregnancies, to allow an earlier prenatal diagnosis and adequate 
management.[7, 34, 35] 
Concerning the morbidity of the neonates with NIHF, all the disorders were 
more frequently found in the deceased group, except for NEC. Despite the fact that the 
only statistically significant difference between deceased and live neonates was the 
frequency of anemia, these results reflect a worst baseline clinical picture, which 
contributes to a higher mortality. 
A large number of postnatal interventions, including pharmacological or invasive 
ones, treatment directed to the underlying condition or supportive measures, are 
available and must be used when necessary. Another important and statistically 
significant result in our study was that survivors received more frequently a specific 
treatment for the underlying disorder than the deceased patients. This means that the 
response to this kind of therapy can revert the hydrops and improve the survival, which 
is extremely encouraging, given the overall poor prognosis associated with NIHF. 
Conversely, thoracocentesis, paracentesis and amines were statistically more 
frequently used in the case of neonatal death compared to the survivors. Likewise, the 
use of mechanical ventilation, oxygen therapy, blood transfusion and antibiotics was 
also more frequently found in the case of deceased patients, although the difference 
was not statistically significant. This probably indicates that these neonates had a 
baseline condition more critical and severe, which justifies the need to use these 
therapies.  
Our study struggle with some limitations. It is a retrospective study, realized in a 
single centre and with a relatively small sample, impairing the generalization of 
conclusions. Another drawback is that our study only included the cases that were 
delivered as NIHF, not including prenatal spontaneous resolution cases, which can 
underestimate the prevalence of NIHF and overestimate the percentage of deaths. 
Larger and prospective studies are needed, in order to obtain statically significant 
conclusions about the best approach in the prenatal period, as well as the best 
management, treatment and follow-up strategy. Long-term outcomes and morbidity of 
NIHF patients are also information of great interest.  
The results of this series may add some useful information to the current 
literature on NIHF, a very rare clinical condition of the newborn. 
 
Conclusion 
The diagnosis and management of NIHF remains a challenge for obstetricians 
and neonatologists. Despite improvements in pre and postnatal healthcare, overall 
mortality rates are high. However, some causes of NIHF are responsive to therapy, 
such as cardiac diseases, which determines a lower mortality and morbidity. 
Furthermore, the prognosis of NIHF varies clearly between different etiological groups. 
For these reasons, we can conclude that the cornerstone of management of NIHF is 
based on the underlying etiology, which allows a better prediction of prognosis, 
selection of pre and postnatal appropriate treatment and assessment of the recurrence 
risk of future pregnancies.  
Findings of this study, along with review of the literature, are essential for a 
better understanding of this complex pathology, thereby allowing individual pre and 
postnatal management and appropriate parental counselling. It is particularly important 
to exclude potentially treatable conditions, such as arrhythmias, as well as genetic 
disorders that have a higher risk of recurrence in future pregnancies. This implies 
timely referral to a specialized centre.  
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Table 1. Maternal and perinatal data of all cases of Non-Immune Hydrops Fetalis. 
Case 
nº 
Year 
Maternal 
age 
(years) 
Gestational 
age at birth 
(weeks) 
Gender 
 
Birth 
weight (g) 
Type of 
gestation 
Type of 
delivery 
Antenatal 
corticosteroids 
therapy 
Prenatal 
diagnostic 
testing 
Prenatal 
NIHF 
diagnosis 
Fetal intervention 
1 1997 20 29 Male 1870 Single C-section Yes Cordocentesis Yes None 
2 1998 28 27 Female 890 Single 
C-section 
Yes None 
Yes 
None 
3 1998 29 34 Female 3260 Single C-section Yes None No None 
4 1999 31 30 Male 2045 Single C-section Yes Amniocentesis Yes None 
5 2000 43 31 Female 1810 Single C-section Yes None Yes None 
6 2001 33 29 Female 1500 Multiple C-section Yes None Yes None 
7 2001 30 36 Male 4270 Single C-section No None 
Yes 
None 
8 2002 27 30 Male 2240 Single C-section Yes None 
Yes 
None 
9 2002 31 32 Female 2228 Single C-section Yes None 
No 
None 
10 2003 26 39 Female 3052 Single Vaginal No None Yes Digoxin 
11 2005 26 31 Female 1320 Single Vaginal Yes Amniocentesis Yes Hydroxyzine, Nifedipine 
12 2006 38 34 Male 2800 Single C-section No None No None 
13 2007 34 32 Male 3100 Single C-section Yes Amniocentesis Yes Digoxin, Sotalol 
14 2007 40 39 Male 3240 Single C-section No Amniocentesis 
Yes 
Digoxin, Flecainide 
15 2007 28 34 Female 3320 Single C-section Yes None 
No 
None 
16 2008 28 31 Female 3342 Single C-section Yes Amniocentesis Yes None 
17 2009 21 31 Male 2435 Single C-section No None Yes Digoxin 
18 2009 32 30 Female 1900 Single C-section No None Yes None 
19 2010 26 34 Female 2605 Single C-section Yes None Yes None 
20 2013 24 37 Male 3045 Single C-section No None 
Yes 
None 
21 2014 28 30 Male 1530 Single C-section Yes Amniocentesis 
Yes 
Thoracocentesis 
22 2015 34 36 Male 2675 Single Vaginal 
Yes 
None Yes 
Digoxin, Flecainide 
23 2016 29 31 Male 2220 Single C-section Yes None Yes Digoxin 
Table 2. Maternal, perinatal data and neonatal morbidity of Non-Immune Hydrops 
Fetalis cases, comparing deceased and survivors 
 
 
*
Chi-square test; 
** Fisher’s exact test; § Independent t test; ¥ Mann Whitney U test 
 
 
  
 Total 
(n=23) 
Deceased 
(n=12) 
Survivors 
(n=11) 
p 
Gender, n (%) 
   Male 
   Female 
 
12 (52.2) 
11 (47.8) 
 
6 (50) 
6 (50) 
 
6 (54.5) 
5 (45.5) 
 
0.827* 
Birth weight (g), mean ± SD 2465.1 ± 806.1 2178.8 ± 958.7 2777.4 ± 461.2 0.074§ 
Maternal age (years), mean ± SD 29.8 ± 5.5 29.9 ± 5.5 29.7 ± 5.8 0.937§ 
Gestational age (weeks), mean ± SD 32.5 ± 3.2 30.6 ± 2.2  34.4 ± 3.1 0.003§ 
Prenatal NIHF diagnosis, n (%) 19 (82.6) 11 (91.7) 8 (72) 0.317** 
Prenatal invasive diagnostic testing, n (%) 7 (30.4) 6 (50) 1 (9.1) 0.069** 
Fetal intervention, n (%) 
   Pharmacological  
   Thoracocentesis  
8 (34.8) 
7 (30.4) 
1 (4.3) 
3 (25.0) 
2 (16.7) 
1 (8.3) 
5 (45.5) 
5 (45.5) 
0 
0.400** 
0.999** 
0.193** 
C-section delivery, n (%) 20 (86.9) 11 (91.7) 9 (81.8) 0.999** 
1st minute APGAR <7, n (%) 18 (78.3) 11 (91.7) 7 (63.6) 0.155** 
5th minute APGAR <7, n (%) 10 (43.5) 6 (50.0) 4 (36.4) 0.414** 
Reanimation, n (%) 13 (56.5) 9 (75.0) 4 (36.4) 0.100** 
Endotracheal tube, n (%) 14 (60.9) 9 (75.0) 5 (45.5) 0.214** 
Intraventricular haemorrhage (≥ grade 3), n (%) 1 (4.3) 1 (8.3) 0 0.999** 
Patent ductus arteriosus, n (%) 10 (43.5) 6 (50.0) 4 (36.4) 0.680** 
Hyaline membrane disease, n (%) 7 (30.4) 4 (33.3) 3 (27.3)  0.999** 
Bronchopulmonary dysplasia, n (%) 3 (13.0) 3 (25.0) 0 0.217** 
Major congenital malformation, n (%) 3 (13.0) 2 (16.7)  1 (9.1) 0.999** 
Anemia, n (%) 14 (60.9) 10 (83.3) 4 (36.4) 0.036** 
Necrotizing enterocolitis, n (%) 1 (4.3) 0  1 (9.1) 0.478** 
Sepsis, n (%) 10 (43.5) 6 (50.0) 4 (36.4) 0.680** 
Days of hospitalization, median (min-max) 15 (0-56) 9.5 (0-41) 15 (2-56)  0.288¥ 
Table 3. Etiology, treatment, and outcome during hospitalization of all cases of Non-immune Hydrops Fetalis. 
Case 
nº 
Year Etiology of NIHF Specific Treatment Amines Diuretics Antibiotics Surfactant 
Blood 
transfusion 
Thoracocentesis 
and/ or 
Paracentesis 
Mechanical 
ventilation 
Outcome 
1 1997 
Toxoplasmosis 
Infection 
None Yes Yes Yes Yes Yes No Yes Dead 
2 1998 Idiopathic None Yes No Yes No Yes No Yes Dead 
3 1998 
Lymphatic 
Dysplasia 
None No No Yes No No Thoracocentesis Yes Survived 
4 1999 Atrial Septal Defect None Yes No Yes No Yes Thoracocentesis Yes Dead 
5 
2000 
Tetrasomy 9p None Yes No Yes Yes Yes Both Yes Dead 
6 2001 
Right-ventricle 
hypoplasia 
None Yes No No No No No No Dead 
7 2001 Idiopathic None Yes No No No No Both Yes Dead 
8 2002 Idiopathic None Yes No No No Yes Both Yes Dead 
9 2002 Sifilis Infection Penicillin Yes No Yes Yes Yes Paracentesis Yes Dead 
10 
2003 Wolff-Parkinson-
White 
Propanolol, Flecainide No No No No No No No Survived 
11 2005 
Inborn error of 
metabolism 
None Yes No Yes No Yes Paracentesis Yes Dead 
12 2006 Atrial Flutter 
Adenosine, Cardioversion. 
Digoxin, Propanolol, 
Flecainide. 
Yes Yes Yes Yes Yes No Yes Survived 
13 2007 Atrial Flutter Atropine, cardioversion Yes Yes Yes Yes Yes Both Yes Dead 
14 2007 
Supraventricular 
Tachycardia 
None No No No No No No No Survived 
15 2007 
Supraventricular 
Tachycardia 
Adenosine, amiodarone. 
Digoxin. 
No Yes Yes Yes Yes No Yes Survived 
16 2008 
Congenital 
Nephrotic 
Syndrome 
Peritoneal dialysis Yes Yes Yes Yes Yes Thoracocentesis Yes Dead 
17 2009 
Supraventricular 
Tachycardia 
Adenosine. Propanolol, 
Flecainide 
No No No Yes No Thoracocentesis Yes Survived 
18 2009 
Supraventricular 
Tachycardia 
Adenosine, Cardioversion. 
Propanolol, Flecainide. 
No No Yes No Yes No No Survived 
19 2010 Wolff-Parkinson-
White 
Propanolol, Flecainide No Yes Yes Yes Yes No Yes Survived 
20 2013 
Cardiac 
Rhabdomyoma 
None No Yes Yes Yes No No Yes Survived 
21 
2014 Lymphatic 
Dysplasia 
None Yes Yes Yes Yes Yes Thoracocentesis Yes Dead 
22 2015 
Supraventricular 
Tachycardia 
Propanolol No Yes No No No No No Survived 
23 2016 
Supraventricular 
Tachycardia 
Adenosine, Amiodarone, 
Cardioversion. Propanolol, 
Flecainide 
No Yes Yes Yes Yes No Yes Survived 
Table 4. Etiology of Non-immune Hydrops Fetalis, comparing deceased and survivors. 
 
 
** Fisher’s exact test 
 
 
 
Table 5.  Treatment of Non-immune Hydrops Fetalis patients during hospitalization, 
comparing deceased and survivors. 
 
 
 
*
Chi-square test;
 ** Fisher’s exact test; ¥ Mann Whitney U test 
 
 
Table 6. Multivariate analysis – predictive factors of mortality. 
 
 OR 95% CI p 
Thoracocentesis or paracentesis 25.24 1.27-503.26 0.034 
Gestational age at birth 0.5 0.29-0.95 0.034 
 
 
 
Total 
(n=23) 
Deceased 
(n=12) 
Survivors 
(n=11) 
p 
Congenital heart disease (structural defect or arrhythmia), n (%) 12 (52.2) 3 (25.0) 9 (81.8) 0.001** 
Idiopathic, n (%) 3 (25.0) 0 3 (13.0) 0.217** 
Congenital TORCH infection, n (%) 2 (8.7) 2 (16.7) 0 0.478** 
Lymphatic dysplasia, n (%) 2 (8.7) 1 (8.3) 1 (9.1) 0.999** 
Chromosomal abnormality, n (%) 1 (4.3) 1 (8.3) 0 0.999** 
Congenital nephrotic syndrome, n (%) 1 (4.3) 1 (8.3) 0 0.999** 
Cardiac rhabdomyoma, n (%) 1 (4.3) 0 1 (9.1) 0.478** 
Inborn errors of metabolism, n (%) 1 (8.3) 0 1 (4.3) 0.999** 
 Total 
(n=23) 
Deceased 
(n=12) 
Survivors 
(n=11) 
p 
Specific treatment, n (%) 11 (47.8) 3 (25.0) 8 (72.7) 0.039** 
Thoracocentesis and/ or Paracentesis, n (%) 11 (47.8) 9 (75.0) 2 (18.2) 0.012** 
Amines, n (%) 14 (60.9) 12 (100.0) 2 (18.2) <0.001** 
Antiarrhythmics, n (%) 10 (43.5) 1 (8.3) 9 (81.8) 0.001** 
Diuretics, n (%) 10 (43.5) 4 (33.3) 6 (54.5) 0.414** 
Antibiotics, n (%) 16 (69.5) 9 (75.0) 7 (63,6) 0.667** 
Surfactant, n (%) 12 (52.2) 6 (50.0) 6 (54.5) 0.827* 
Parenteral nutrition, n (%) 16 (69.5) 8 (66.7) 8 (72.7) 0.999** 
Blood transfusion, n (%) 15 (65.2) 10 (83.3) 5 (45.4) 0.089** 
Mechanical Ventilation, n (%) 18 (78.3) 11 (91.7) 7 (63.6) 0.155** 
Mechanical Ventilation (days),  median (min-max) 5 (0-41) 9.5 (0-41) 5 (0-23) 0.235¥ 
Oxygen therapy, n (%) 17 (73.9) 11 (91.7) 6 (54.5) 0.069** 
Oxygen therapy (days), median (min-max) 2 (0-41) 9.5 (0-41) 1 (0-41) 0.151¥ 
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Apêndice 1. 
 
Prenatal, perinatal and neonatal data 
1. Demographics 
Birth Date:  __/__/____ 
Sex:  F      M 
Gestacional age: _____ weeks  
Birth weight: ____ g 
 
2. Gestation 
Maternal age: ____ years 
Multiple gestation:  no    yes  
Vigilance:  no   yes 
Prenatal Corticosteroids:  no   yes 
Smoking during pregnancy:  no   yes 
Drugs during pregnancy:  no   yes 
Gestational Diabetes:  no   yes 
Chronic maternal hypertension:  no    yes 
Pre-eclampsia:  no   yes 
Eclampsia:  no    yes 
HELLP Syndrome:  no    yes 
Streptococcus agalactiae (group B):  no   yes  
Prenatal invasive diagnostic testing:  no   yes       
TORCH screening:  no   yes 
Fetal karyotyping:  no   yes 
Thoracoamniotic shunting:  no   yes 
Intrauterine transfusion:  no   yes 
Pharmacological treatment:  no   yes 
Thoracocentesis:  no   yes 
Prenatal NIHF diagnosis:  no   yes 
 
3. Delivery 
C-section:  no   yes 
Premature Rupture of Membranes:  no   yes 
Intrapartum antibiotics:  no   yes 
APGAR (1st and 5th minutes):  ___/___ 
Resuscitation:  no   yes 
Endotracheal Tube:  no   yes 
 
4. Neonatal Period  
 
TORCH group infection:  no   yes  
Congenital heart disease:  no   yes 
 Structural defect:  no   yes _________ 
 Arrhythmia:  no   yes _______ 
Lymphatic Dysplasia:  no   yes 
Congenital Nephrotic syndrome:  no   yes 
Chromosomal abnormality:  no   yes 
Inherited Metabolic disease:  no   yes 
Fetal tumor:  no   yes 
  
Congenital hemodiaphragmatic hernia:  no   yes 
Pulmonary Hipertension:  no   Non Severe   Severe 
 Cause: _______________  
Pneumonia:  no   yes  
Bronchopulmonary dysplasia:  no   yes 
Hyaline membrane disease:  no   yes 
Sepsis:  no   yes 
Patent ductus arteriosus:  no   yes 
Major Congenital Malformation:  no   yes 
Twin-to-twin transfusion syndrome:  no   yes 
Feto-maternal transfusion:  no   yes 
Anemia:  no   yes 
Necrotizing enterocolitis (grade ≥ 2A Bell):  no   yes 
Intraventricular hemorrhage (grade ≥ 3):  no   yes  
 
Fetal karyotyping:  no   yes 
Thoracocentesis:  no   yes 
Transfusion:  no   yes 
Inhaled Nitric Oxid:  no   yes 
Sildenafil:  no   yes 
Prostagladins:  no   yes 
Amines:  no   yes 
Antiarrhythmic:  no   yes 
Diuretics:  no   yes  
Surfactant:  no   yes 
Antibiotics:  no   yes 
Specific treatment:  no   yes 
Extracorporeal Membrane Oxygenation:  no   yes 
Parenteral Feeding:  no   yes  
Conventional mechanical ventilation (>12h):  no   yes   (duration ___ days) 
Oxygen supplementation:  no   yes   (duration ___ days) 
 
Days at NICU: ____ 
Deceased:  no   yes  
Autopsy:  no   yes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
